奥洛组单抗(抗白细胞介素-6 单克隆抗体)联合甲氨蝶呤治疗肿瘤坏死因子抑制剂控制不佳的类风湿关节炎患者:一项随机对照 III 期研究的疗效与安全性结果
这项 24 周多中心、安慰剂对照、双盲 III 期研究纳入 368 例肿瘤坏死因子抑制剂应答不足(TNFi-IR)的类风湿关节炎患者,按 2:2:1 随机接受奥洛组单抗(OKZ)64 mg 每 2 周一次、每 4 周一次或安慰剂联合甲氨蝶呤。第 12 周 ACR20 应答率分别为 60.9%、59.6% 和 40.6%(两项比较均 p<0.01),DAS28(CRP)<3.2 的达成也显著 favoring OKZ 组。结论认为直接抑制 IL-6 可显著改善症状体征,安全性特征与 IL-6 受体单克隆抗体相似。
要点
- 第 12 周 ACR20:OKZ 每 2 周组 60.9%、每 4 周组 59.6%,均高于安慰剂组 40.6%(两项比较 p<0.01)。
- DAS28(CRP)<3.2 的达成在 OKZ 两组均显著优于安慰剂组。
- 治疗中出现严重不良事件:OKZ 每 2 周组 7%、每 4 周组 3.2%、安慰剂组无。
核心结论
- 在 TNFi-IR 的类风湿关节炎患者中,OKZ 直接抑制 IL-6 较安慰剂显著改善疾病症状体征,安全性特征与 IL-6 受体单克隆抗体相似。
研究设计与样本
- 24 周多中心、安慰剂对照、双盲 III 期研究,368 例患者按 2:2:1 随机接受皮下 OKZ 64 mg 每 2 周一次、OKZ 64 mg 每 4 周一次或安慰剂,均联合甲氨蝶呤;第 16 周安慰剂组患者随机转用任一 OKZ 方案。
- 主要终点为第 12 周达到美国风湿病学会 20% 应答(ACR20)的患者比例;主要次要疗效终点为第 12 周 DAS28(CRP)<3.2;同时评估安全性与免疫原性。
主要发现
- 第 12 周 ACR20 应答率:OKZ 每 2 周组 60.9%、OKZ 每 4 周组 59.6%、安慰剂组 40.6%(两项比较均 p<0.01)。
- 第 12 周 DAS28(CRP)<3.2 的达成在 OKZ 两组与安慰剂组间差异显著, favoring OKZ 组。
- 疗效与患者报告结局的改善维持至 24 周,第 16 周从安慰剂转用 OKZ 的患者也观察到改善。
- 治疗中出现严重不良事件:OKZ 每 2 周组 7%、OKZ 每 4 周组 3.2%、安慰剂组无。
关键数值与推荐
- 主要终点第 12 周 ACR20:OKZ 每 2 周组 60.9% vs 安慰剂组 40.6%,OKZ 每 4 周组 59.6% vs 安慰剂组 40.6%(两项比较均 p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs). METHODS: In this 24-week multicentre, placebo-controlled, double-blind study, the patients were randomised in a 2:2:1 ratio to receive subcutaneously administered OKZ 64 mg once every 2 weeks (q2w), OKZ 64 mg once every 4 weeks (q4w) or PBO plus methotrexate. At week 16, the patients on PBO were randomised to receive either OKZ regime. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20% (ACR20) response at week 12. Disease Activity Score 28-joint count C-reactive protein (DAS28 (CRP))<3.2 at week 12 was the major secondary efficacy endpoint. Safety and immunogenicity were assessed. RESULTS: In 368 patients randomised, ACR20 response rates were 60.9% in OKZ q2w, 59.6% in OKZ q4w and 40.6% in PBO (p<0.01 for both comparisons). Achievement of DAS28 (CRP) <3.2 was significantly different, favouring the OKZ arms. Improvements in efficacy and patient-reported outcomes were maintained throughout 24 weeks and were noted after week 16 in patients who switched from PBO.Dose-related treatment-emergent serious adverse events were 7% in OKZ q2w, 3.2% in OKZ q4w and none in the PBO group. CONCLUSIONS: Direct inhibition of IL-6 with OKZ resulted in significant improvements in the signs and symptoms of rheumatoid arthritis compared with PBO in TNF-IR patients with a similar safety profile as observed for monoclonal antibodies to the IL-6 receptor. TRIAL REGISTRATION NUMBER: NCT02760433.
引用
- Feist E, Fatenejad S, Grishin S, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022. PMID: 36109142. doi:10.1136/ard-2022-222630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。